Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.

@article{OConnor2008RifampinAR,
  title={Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.},
  author={Jennifer R O'Connor and Minerva A Galang and Susan P. Sambol and David W. Hecht and Gayatri Vedantam and Dale N. Gerding and Stuart Johnson},
  journal={Antimicrobial agents and chemotherapy},
  year={2008},
  volume={52 8},
  pages={2813-7}
}
Rifaximin, a poorly absorbed rifamycin derivative, is a promising alternative for the treatment of Clostridium difficile infections. Resistance to this agent has been reported, but no commercial test for rifaximin resistance exists and the molecular basis of this resistance has not been previously studied in C. difficile. To evaluate whether the rifampin… CONTINUE READING